Abstract
Background: To evaluate the concordance between HER2 status in both surgical specimens and matched endoscopic specimens of gastric adenocarcinoma patients.
 Methods: Records of 52 patients with gastric adenocarcinoma diagnosed by upper GI endoscopy, treated by gastrectomy and Her2 status assessed (by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH)) from June 2014 through July 2016 in HCMC Oncology Hospital were studied and presented in case series. Her2-positive status was defined by a score 3+ in IHC, or 2+ with a positive FISH test.
 Results: + Her2-positive status was identified in 9.6%.
 + The concordance of Her2 status between endoscopic biopsy and surgical specimens was 98% (Kappa=0.879).
 Conclusion: + There was a very high concordance between the Her2 status results performed on surgical specimens and matched endoscopic specimens.
 + Her2 status assessed on endoscopic biopsy specimens could be reliable for treatment decisions using anti-Her2 agents in patients with advanced gastric carcinoma
Highlights
To evaluate the concordance between HER2 status in both surgical specimens and matched endoscopic specimens of gastric adenocarcinoma patients
Records of 52 patients with gastric adenocarcinoma diagnosed by upper GI endoscopy, treated by gastrectomy and Her[2] status assessed (by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH)) from June 2014 through July 2016 in HCMC Oncology Hospital were studied and presented in case series
Results: + Her2-positive status was identified in 9.6%. + The concordance of Her[2] status between endoscopic biopsy and surgical specimens was 98% (Kappa=0.879)
Summary
Background: To evaluate the concordance between HER2 status in both surgical specimens and matched endoscopic specimens of gastric adenocarcinoma patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have